Hidden Camera Video Generates Empathy for Those Living with Diabetes

Accolade to Acquire PlushCare

Accolade to begin offering virtual primary care and mental health consultations directly to members as a result of the acquisition.

CareDx to Present New Heart Transplant Data at the International Society for Heart and Lung Transplantation Annual Meeting

Experts will present its latest heart research, which was accepted at the International Society for Heart and Lung Transplantation (ISHLT) Annual Meeting & Scientific Sessions, set to take place between April 24-28, 2021.

Dermatology Experts Present Latest Information at AAD VMX 2021

The AAD VMX 2021, a virtual meeting experience taking place April 23-25, will feature the latest information on skin, hair, and nails, presented by world-renowned experts in the field of dermatology.

December 11, 2018

Dexcom released a hidden camera video showing the shocked reactions of people asked to prick their finger before eating, a task that most people with diabetes do more than eight times per day to check their glucose levels. The video is part of the company’s national #NoMoreFingerpricks campaign to raise critical awareness about the complexity and seriousness of diabetes and to advocate for innovative technologies like continuous glucose monitoring (CGM) to become the standard in patient care.

“We filmed this video to show the world the unnecessary painfulness of fingerpricks many people with diabetes do every day,” said Kevin Sayer, president and CEO of Dexcom. “With almost 1.5 million people in the United States living with Type 1 diabetes, it is critical that healthcare providers talk to their patients about CGM and other innovative diabetes management technologies that can improve the health and quality of life for people with diabetes.”

Data from a survey released last month shows there is low awareness of CGM among people with Type 1 diabetes, despite the fact CGM eliminates painful fingerpricks, increases time in target glucose range, lowers A1C, decreases hypoglycemia and improves overall quality of life for people with diabetes.1-5

In addition to filming the video, Dexcom launched a social media campaign on November 1 which reached millions of people around the world and raised $25,000 for diabetes advocacy and research. For every photo or video posted to Facebook and Instagram using the hashtag #NoMoreFingerpricks, Dexcom committed to donating $1 to Beyond Type 1, a diabetes nonprofit working to educate, advocate and cure Type 1 diabetes.

“We’re grateful for the revolutionary new technology that is now available to people with Type 1 diabetes,” said Thom Scher, Beyond Type 1 CEO. “It was an inspiring experience to celebrate National Diabetes Awareness Month with Dexcom who is on the forefront of innovation in diabetes technology. This generous donation will help our organization continue to provide critical resources and support to the diabetes community.”


References

  1. Šoupal J, Petruželková L, Fleka M et al. Comparison of Different Treatment Modalities for Type 1 Diabetes, Including Sensor-Augmented Insulin Regimens, in 52 Weeks of Follow-Up: A COMISAIR Study. Diabetes Technology & Therapeutics. 2016;18(9):532-538.
  2. Beck RW, Riddlesworth T, Ruedy K, et al. Effect of Continuous Glucose Monitoring on Glycemic Control in Adults With Type 1 Diabetes Using Insulin Injections: The DIAMOND Randomised Clinical Trial. JAMA. 2017;317(4):371-378.
  3. Lind M, Polonsky W, Hirsch IB, et al. Continuous Glucose Monitoring vs Conventional Therapy for Glycemic Control in Adults With Type 1 Diabetes Treated With Multiple Daily Insulin Injections: The GOLD Randomised Clinical Trial. JAMA. 2017;317(4):379-387.
  4. Reddy M, Jugnee N, El Laboudi A, Spanudakis E, Anantharaja S, Oliver N. A randomised controlled pilot study of continuous glucose monitoring and flash glucose monitoring in people with Type 1 diabetes and impaired awareness of hypoglycaemia. Diabet Med. 2017.
  5. Heinemann L, Freckmann G, Ehrmann D, et al. Real-time continuous glucose monitoring in adults with type 1 diabetes and impaired hypoglycaemia awareness or severe hypoglycaemia treated with multiple daily insulin injections (HypoDE): a multicentre, randomised controlled trial. Lancet. 2018.
spot_img

DON'T MISS

Subscribe to Medical Device News Magazine

Related Articles